Galectin-1 pulls the strings on VEGFR2

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Anti-vascular endothelial growth factor (VEGF) cancer immunotherapy targets angiogenesis but development of resistance in patients is common. In this issue of Cell, Croci et al. identify a complex set of mechanisms by which galectin-1 prolongs cell-surface retention of VEGF receptor 2 (VEGFR2) and stimulates VEGF-independent tumor angiogenesis.

Original languageEnglish (US)
Pages (from-to)625-626
Number of pages2
JournalCell
Volume156
Issue number4
DOIs
StatePublished - Feb 13 2014

Fingerprint

Galectin 1
Vascular Endothelial Growth Factor Receptor
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor-2
Immunotherapy
Tumors
Neoplasms

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Galectin-1 pulls the strings on VEGFR2. / Stanley, Pamela.

In: Cell, Vol. 156, No. 4, 13.02.2014, p. 625-626.

Research output: Contribution to journalArticle

Stanley, Pamela. / Galectin-1 pulls the strings on VEGFR2. In: Cell. 2014 ; Vol. 156, No. 4. pp. 625-626.
@article{56f15a92f94c4e399ddce0bce7614a4c,
title = "Galectin-1 pulls the strings on VEGFR2",
abstract = "Anti-vascular endothelial growth factor (VEGF) cancer immunotherapy targets angiogenesis but development of resistance in patients is common. In this issue of Cell, Croci et al. identify a complex set of mechanisms by which galectin-1 prolongs cell-surface retention of VEGF receptor 2 (VEGFR2) and stimulates VEGF-independent tumor angiogenesis.",
author = "Pamela Stanley",
year = "2014",
month = "2",
day = "13",
doi = "10.1016/j.cell.2014.01.059",
language = "English (US)",
volume = "156",
pages = "625--626",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "4",

}

TY - JOUR

T1 - Galectin-1 pulls the strings on VEGFR2

AU - Stanley, Pamela

PY - 2014/2/13

Y1 - 2014/2/13

N2 - Anti-vascular endothelial growth factor (VEGF) cancer immunotherapy targets angiogenesis but development of resistance in patients is common. In this issue of Cell, Croci et al. identify a complex set of mechanisms by which galectin-1 prolongs cell-surface retention of VEGF receptor 2 (VEGFR2) and stimulates VEGF-independent tumor angiogenesis.

AB - Anti-vascular endothelial growth factor (VEGF) cancer immunotherapy targets angiogenesis but development of resistance in patients is common. In this issue of Cell, Croci et al. identify a complex set of mechanisms by which galectin-1 prolongs cell-surface retention of VEGF receptor 2 (VEGFR2) and stimulates VEGF-independent tumor angiogenesis.

UR - http://www.scopus.com/inward/record.url?scp=84894156655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894156655&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2014.01.059

DO - 10.1016/j.cell.2014.01.059

M3 - Article

VL - 156

SP - 625

EP - 626

JO - Cell

JF - Cell

SN - 0092-8674

IS - 4

ER -